A Trump-appointed federal judge is expected to hand down a decision this month that could block access to mifepristone, one of the two drugs used in the recommended medication abortion regimen. The consequences of such a decision would not only be seen in states with abortion restrictions but in states where abortions still remain legally accessible, too.
The Food and Drug Administration (FDA) approved mifepristone for the medical termination of pregnancy over two decades ago. But a lawsuit filed last November alleges that the longstanding approval should be revoked because it was allegedly based on incomplete data. The anti-abortion organization Alliance for Hippocratic Medicine claims that the FDA failed to protect women when it approved the drug.
